PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

The Phosphoinositide 3-Kinase Pathway

2002 • 5,427 citations

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

2004 • 4,992 citations

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

2004 • 3,304 citations

ERBB receptors and cancer: the complexity of targeted inhibitors

2005 • 3,200 citations

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 • 3,101 citations

Somatic mutations affect key pathways in lung adenocarcinoma

2008 • 2,653 citations

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

2000 • 2,394 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

2008 • 1,579 citations

A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer

2007 • 1,562 citations

KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

2008 • 1,432 citations

High-throughput oncogene mutation profiling in human cancer

2007 • 995 citations

Mutant PIK3CA promotes cell growth and invasion of human cancer cells

2005 • 873 citations

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 • 827 citations

Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies

2007 • 817 citations

The PIK3CA gene is mutated with high frequency in human breast cancers

2004 • 654 citations

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

2006 • 516 citations

Oncogenic PI3K and its role in cancer

2005 • 505 citations

Mutation of the PIK3CA oncogene in human cancers

2006 • 478 citations

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

2008 • 391 citations

The prevalence of PIK3CA mutations in gastric and colon cancer

2005 • 333 citations

Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers

2008 • 310 citations

PIK3CA Mutation in Colorectal Cancer: Relationship with Genetic and Epigenetic Alterations

2008 • 233 citations

Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer.

1999 • 206 citations

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

2008 • 176 citations

Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3‐kinase/AKT signaling pathway in thyroid tumors

2008 • 134 citations

PIK3CA mutation is predictive of poor survival in patients with colorectal cancer

2007 • 129 citations

Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population

2008 • 89 citations

PIK3CAcancer mutations display gender and tissue specificity patterns

2007 • 83 citations

Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents

2008 • 74 citations

Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data

2006 • 22 citations